Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for 

as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.

Daiichi Sankyo, AstraZeneca Withdraw EU MAA for Dato-DXd in Advanced Nonsquamous NSCLC

Confidence, support, and hard work paved the way for an exceptionally successful career for Edward S. Kim, MD, MBA, who has a cemented mission in diversifying clinical trials and improving quality of life.

Rewriting the Rules for a Better Future of Cancer Care

In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.

Combination Regimens Make Their Mark in Frontline HCC

Ashling Wahner joined MJH Life Sciences in 2022. She produces 

, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.

Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

Continuing Education

26th Annual International Lung Cancer Congress®

Joseph R. Mikhael, MD, MEd, FRCPC, FACP; Ajai Chari, MD; Caitlin Costello, MD; Krina Patel, MD, MSc

Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat

George M. Rodgers III, MD, PhD; Patricia A. Ford, MD; Sidharth Anand, MD, MBA

Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?

Andrew Kuykendall, MD; Naveen Pemmaraju, MD; Barbara Mora, MD; Gabriela Hobbs, MD

Show Me the Data: How Do We Navigate the Latest Evidence on Novel Therapies, Combinations, and Clinical Trials Across MPN Care in the Context of Current Treatment Algorithms?

Towards Personalized Treatment Approaches in Soft Tissue Sarcomas

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

22nd Annual Winter Lung Cancer Conference®

Brendon M. Stiles, MD; Jamie E. Chaft, MD; Balazs Halmos, MD, MS

 Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

Tanios Bekaii-Saab, MD, FACP; Aiwu Ruth He, MD, PhD; Eugene J. Koay, MD

The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape

42nd Annual Miami Breast Cancer Conference®

Heather McArthur, MD, MPH; William J. Gradishar, MD, FASCO, FACP; Jennifer Keating Litton, MD, MHCM; Debu Tripathy, MD

 The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…

Nicole Lamanna, MD; William Wierda, MD, PhD; Jennifer A. Woyach, MD

Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions

Tanios Bekaii-Saab, MD, FACP; Richard S. Finn, MD; Aiwu Ruth He, MD, PhD; Eugene J. Koay, MD

18th Annual New York GU Cancers Congress™

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

Andre H. Goy, MD; Marco L. Davila, MD, PhD; Ajay K. Nooka, MD, MPH, FACP

Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy

Kevin Kalinsky, MD, MS; Komal Jhaveri, MD, FACP; Reshma L. Mahtani, DO; Kelly McCann, MD, PhD

Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care

E. Gabriela Chiorean, MD, FASCO; John L. Marshall, MD; Diana L. Hanna, MD; Syma Iqbal, MD; Heloisa P. Soares, MD, PhD Associate Professor 

  Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

Exploring the Benefits and Risks of AI in Oncology

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

Karen M. Winkfield, MD, PhD; Narjust Florez, MD, FASCO; Gilberto de Lima Lopes Junior, MD, MBA, FASCO; Coral Olazagasti, MD; Vonetta M. Williams, MD, PhD

 Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Peter Robert Galle, MD, PhD; Amit Singal, MD, MS; Linda L. Wong, MD; Ghassan Abou-Alfa, MD, MBA; Han Chong Toh, MD 

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

Matt Lunning DO, FACP; Kami Maddocks, MD; Grzegorz S. Nowakowski, MD, FASCO; Sarah C. Rutherford, MD

Contextualizing Advances in Relapse Refractory DLBCL: Navigating Biomarkers, Emerging Data, and Adverse Event Management to Transform Patient Care

Burst CME™: Tackling Adverse Events With Targeted Therapies for Diffuse B-Cell Lymphoma

Matt Lunning, DO, FACP; Sarah C. Rutherford, MD

 Biomarkers in Diffuse Large B-Cell Lymphoma: Empowering Treatment Decisions to Improve Outcomes

Matt Lunning, DO, FACP; Grzegorz S. Nowakowski, MD., FASCO

 Treating Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Current Options and Emerging Approaches

Corey Cutler, MD, MPH, FRCP(C); Carrie L. Kitko, MD

BURST Expert Illustrations and Commentaries™: Exploring the Mechanistic Rationale for CSF-1R– Directed Treatment in Chronic GVHD

Asim V. Farooq, MD; Joann Kang, MD; Nita Lee, MD, MPH

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

20th Annual New York Lung Cancers Symposium®

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Richard S. Finn, MD; Anthony B. El-Khoueiry, MD; Pierre Gholam, MD; Lipika Goyal, MD

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Kathleen N. Moore, MD, MS, FASCO; Prof Susana Banerjee, MBBS, MA, FRCP, PhD

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Upcoming CME Events & Activities

EVENTS

ACTIVITIES

Latest Conference Coverage